Ayako Tsuboya, Yutaro Kubota, Hiroo Ishida, Ryotaro Ohkuma, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Takuya Tsunoda, Yasutsuna Sasaki, Natsumi Matsumoto, et al. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Cancer chemotherapy and pharmacology. 2021. 88. 3. 543-553
Koki Katayama, Shimon Nakashima, Hiroo Ishida, Yutaro Kubota, Masataka Nakano, Tatsuki Fukami, Yasutsuna Sasaki, Ken-Ichi Fujita, Miki Nakajima. Characteristics of miRNA-SNPs in healthy Japanese subjects and non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma patients. Non-coding RNA research. 2021. 6. 3. 123-129
Yuya Hirasawa, Kiyoshi Yoshimura, Hiroto Matsui, Yutaro Kubota, Hiroo Ishida, Jun Arai, Masashi Sakaki, Nao Oguro, Midori Shida, Makoto Taniguchi, et al. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine. 2021. 100. 23. e25774
Yutaro Kubota, Kiyoshi Yoshimura, Kazuyuki Hamada, Yuya Hirasawa, Midori Shida, Makoto Taniguchi, Hiroto Matsui, Hirotsugu Ariizumi, Tomoyuki Ishiguro, Norihiro Suzuki, et al. Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer. IN VIVO. 2021. 35. 3. 1865-1875
Kiyohiro Ando, Kazuyuki Hamada, Midori Shida, Ryotaro Ohkuma, Yutaro Kubota, Atsushi Horiike, Hiroto Matsui, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, et al. A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. Cancer immunology, immunotherapy : CII. 2021. 70. 2. 337-348
